Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05266092

Activation of the Contact System and the Immune System in Patients With Chronic Kidney Disease.

Patients with end-stage renal disease undergoing hemodialysis (HD) are burdened with extremely high mortality rates (15% per year) and during the early stage (≤120days) the mortality rate is even higher (27% per year). Cardiovascular complications and bloodstream infections (BSIs) account for the vast majority of deaths in HD patients. In Denmark, BSIs occur in 14% of HD patients per year and is most frequently caused by Staphylococcus aureus (44%). The most frequent infectious complication is endocarditis that has fatal outcomes in ≈50% of the cases. Overall, 10% of HD patients die within 30 days after a positive blood culture for S. aureus. This project aims to answer key questions regarding HD patients' decreased ability to fight S. aureus BSIs and in particular the potential exacerbating effect of HD. We hypothesize that HD patients' blood is significantly compromised by the process of HD, to an extend that lowers immunoactivity against S. aureus. Moreover, we hypothesize, that contact activation promotes the coagulability of blood thus promoting biofilm formation by S. aureus which increases the overall risk of BSI. We will test these hypotheses by collecting blood and analyzing the inflammation and coagulation status in plasma samples from participants before and after HD. We will compare the level of the inflammatory markers in plasma from participants undergoing HD (n=180) to the level in plasma samples from three control groups: healthy volunteers (n=120), participants with renal disease not in dialysis (n=60) and participants undergoing peritoneal dialysis (n=40).

Recruiting

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Participants with chronic kidney disease undergoing hemodialysis Inclusion criteria

  • Age >18 years
  • Chronic kidney disease
  • Hemodialysis

Exclusion criteria

  • Acute kidney disease

Participants with chronic kidney disease, not in dialysis Inclusion criteria

  • Age >18 years
  • Chronic kidney disease (eGFR from <15 to 44)

Exclusion criteria

  • Acute kidney disease
  • Hemodialysis
  • Peritoneal dialysis

Participants with chronic kidney disease undergoing peritoneal dialysis Inclusion criteria

  • Age >18 years
  • Chronic kidney disease
  • Peritoneal dialysis

Exclusion criteria

  • Acute kidney disease

Healthy volunteers Inclusion criteria

  • Age >18 years
  • Blooddonors

Exclusion criteria

  • NA

Treatment and study plan

observational study

Other

Observational study

Primary outcomes

  1. Plasma level of cHK

    Time frame: At enrollment

    cHK is the final activation product of the contact activation system

Study contacts

Contact information is provided by the study sponsor or research team.

Katrine Pilely, PhD

CONTACT

[email protected]

0045 20963328

Sponsors and collaborators

Lead sponsor

Odense University Hospital

Other

Collaborators

  • University of Southern Denmark

Registry information

Official study title

Activation of the Contact System and the Immune System in Patients With Chronic Kidney

Acronym: AKIM-CKD

Important dates

Study start
2022
Primary completion
2023
Study completion
2032
First posted
Mar 4, 2022
Registry last updated
Nov 15, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.